Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ridding suspect epitopes from AD vaccine

The biochemical events leading to the brain degeneration in Alzheimer's disease involve the deposition of beta-amyloid protein, an abnormal fibrillar protein, into brain tissue and vessel walls. Strategies to reduce the level of beta-amyloid have included development of a therapeutic vaccine directed against the

Read the full 448 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE